Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Varese – page 37

2 655 clinical trials in Varese, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Varese at a glance
2 655
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 655 trials in Varese

Open in trial search

Bladder transitional cell carcinoma

Recruiting

A study comparing erdafitinib delivery system to chemotherapy for patients with high-risk non-muscle-invasive bladder cancer who received BCG treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib
  • Sponsor:Janssen Cilag International

Renal cell carcinoma

Recruiting

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Adenocarcinoma gastric+2

Recruiting

A study comparing injection under the skin versus infusion into the vein of tislelizumab with chemotherapy for patients with advanced gastric or gastroesophageal junction cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tislelizumab
  • Sponsor:BeOne Medicines AG

Hernia repair

Recruiting

A Study of Botulinum Toxin Type A for Preparing the Abdominal Wall Before Surgery in Patients with Large Complex Hernias

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Azienda Socio Sanitaria Territoriale Ovest Milanese

Breast cancer+2

Recruiting

A Study of Datopotamab Deruxtecan for Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer That Did Not Respond to Hormone Therapy

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Datopotamab Deruxtecan
  • Sponsor:Astrazeneca AB

Immune thrombocytopenia

Recruiting

A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia to Evaluate Long-term Safety and Effectiveness

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mezagitamab
  • Sponsor:Takeda Development Center Americas Inc.

Hypotension

Recruiting

Testing Bisoprolol in Patients with Acute or Recurrent Pericarditis to Reduce Symptoms and Prevent Recurrence

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bisoprolol
  • Sponsor:Azienda Sanitaria Universitaria Friuli Centrale

Adenomatous polyposis coli

Recruiting

A study testing sirolimus to slow disease progression in patients with familial adenomatous polyposis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sirolimus
  • Sponsor:Biodexa Limited

Anaemia

Recruiting

Study of luspatercept for patients with rare inherited anemias to reduce transfusion needs and improve hemoglobin levels

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Eurobloodnet Association

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

A Study of IMVT-1402 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy to Prevent Disease Relapse

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Immune thrombocytopenia

Recruiting

A Study of Mezagitamab Compared to Placebo for Adults with Chronic Primary Immune Thrombocytopenia

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mezagitamab
  • Sponsor:Takeda Development Center Americas Inc.

Endometrial cancer+1

Recruiting

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:DB-1303
  • Sponsor:BioNTech SE

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Varese

What the registry says about research in the country

01 Hematologic Oncology

Groundbreaking research focusing on blood cancers and lymphomas, including studies of novel therapies for acute myeloid leukemia and chronic myeloid leukemia. Clinical trials are evaluating innovative treatment combinations and maintenance strategies.

  • Follicular Lymphoma Treatment Optimization
  • Leukemia Targeted Therapies
  • B-cell Lymphoma Management

Investigations include maintenance therapies and comparison of shortened versus standard chemotherapy protocols combined with immunotherapy.

02 Thoracic Oncology

Comprehensive studies on non-small cell lung cancer and pleural mesothelioma, exploring innovative combination therapies and targeted treatments for specific genetic mutations.

  • EGFR-TKI Sequencing Studies
  • Immunotherapy Combinations
  • Targeted Molecular Therapies

Research focuses on personalized treatment approaches and novel drug combinations to improve patient outcomes.

03 Cardiovascular Medicine

Advanced research in cardiovascular disease and thrombosis, with trials examining innovative treatments for reducing cardiovascular events and managing blood clots.

  • Lipoprotein Management
  • Deep Vein Thrombosis Treatment
  • Cardiovascular Risk Reduction

Studies aim to evaluate new therapeutic approaches for preventing major cardiovascular events and improving patient outcomes.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.